Schering-Plough’s K-Dur Pay-for-Delay Ruling Reversed

Merck & Co.’s Schering-Plough unit must face a challenge to its agreement with competitors to keep generic versions of its drug K-Dur off the market, an appeals court ruled, reversing a lower-court antitrust decision.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.